Percutaneous Device Therapy to Prevent and Treat Acute Decompensated Heart Failure
- Jerry EstepEmail Jerry Estep
Acute decompensated heart failure (ADHF) is the most common cause for hospitalization among Medicare beneficiaries and is associated with substantial morbidity and mortality. Approximately 4% of patients will die during their hospitalization and 44% will be re-admitted within six months.1•3 In a subset of patients with relative hypotension and cardiorenal syndrome (renal dysfunction at the time of admission or worsening renal function during therapy), the inpatient mortality rate for ADHF increases to 21%.1
The associated economic costs are equally as staggering, w·1th two-thirds of the annual $25 billion heart failure costs attributable to managing ADHF. Given the poor clinical outcomes of patients with ADHF and the high healthcare-related costs, there is an urgent need to adopt aggressive strategies that may favorably alter the course of this increasingly common and potentially deadly condition. This review will highlight the evolving role of percutaneous device therapy to monitor hemodynamics, reduce ventricular filling pressures, and improve end organ perfusion in patients with advanced ADHF.
- Published on 1 Jan 2009
- Peer Reviewed